A Review on the Relationship between SGLT2 Inhibitors and Cancer
This review examines the potential association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and cancer risk. Early clinical trials of dapagliflozin indicated an imbalance in reported cases of breast and bladder cancer, raising safety concerns. However, these findings lacked statistical significance and may be attributed to early cancer detection rather than